http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11391740-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0acc7fd312a68983fb8b9d120043467e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9268c6f2f242f2aa46ccc25767cc48d4 |
| publicationDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11391740-B2 |
| titleOfInvention | Methods and materials for identifying and treating cancer |
| abstract | This document provides methods and materials involved in identifying and/or treating mammals having a treatment-resistant prostate cancer (e.g., an enzalutamide-resistant, castration-resistant prostate cancer). For example, methods and materials for identifying a mammal (e.g., a human) having treatment-resistant prostate cancer (e.g., an enzalutamide-resistant, castration-resistant prostate cancer) as having an elevated level of one or more polypeptides (e.g., one or more of a CXXC5, a CXXC4, a TET2, an ID1, an ID3, and/or a PFN2 polypeptide) in treatment-resistant prostate tissue are provided. Methods and materials for administering one or more targeted therapies with or without one or more chemotherapeutic agents to a mammal having treatment-resistant prostate cancer identified as having an elevated level of one or more polypeptides (e.g., one or more of a CXXC5, a CXXC4, a TET2, an ID1, an ID3, and/or a PFN2 polypeptide) in treatment-resistant prostate tissue also are provided. |
| priorityDate | 2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 623.